Clinical oncology pathways are an important tool, helping cancer care providers and their patients to zero in on the most appropriate care plan. But a treating professional’s decision to depart from the recommendations of these decision-support resources may be well-founded and in the patient’s best interests, research being presented at the American Society of Clinical Oncology (ASCO) 2020 virtual meeting shows. 

In a study to be presented at the ASCO 2020 virtual meeting, a Roswell Park team reports that in many cases, targeted and immunotherapeutic approaches may reduce the risk of therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) compared to chemotherapy-based treatment strategies.

A team from Roswell Park Comprehensive Cancer Center contributed to a group of 10 interrelated studies on tobacco use that shed light on key usage patterns and offered a surprising finding about e-cigarette use.

A possible new strategy for treating pancreatic cancer highlights the promise of collaboration between experts in both precision medicine and immunology. The findings from a team led by Agnieszka Witkiewicz, MD, and Erik Knudsen, PhD, at Roswell Park Comprehensive Cancer Center and published today in the journal Gut suggest a combination treatment approach that can make some breakthrough immunotherapy drugs effective for more patients with pancreatic cancer.